Currently, the systemic individualized treatment of breast cancer is guided by molecular subtype, which was defined according to the expression status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67. The gene discussed is ESR1; the disease is breast carcinoma.